<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907593</url>
  </required_header>
  <id_info>
    <org_study_id>SASSIE-001</org_study_id>
    <nct_id>NCT02907593</nct_id>
  </id_info>
  <brief_title>Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial</brief_title>
  <acronym>SASSIE</acronym>
  <official_title>Steroids and Surfactant in Extremely Low Gestation Age Infants Pilot Dose Escalation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynthia McEvoy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Florida Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II open-label study to determine the lowest, safe, effective dose of
      budesonide given with calfactant as the vehicle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II open-label study to determine the lowest safe, effective dose of
      budesonide given with calfactant as the vehicle; the investigators will perform an unblinded
      dose escalation study. The investigators will administer four dosing levels of budesonide
      suspended in calfactant beginning with 0.025 mg/kg of budesonide administered to 8 extremely
      low gestational age newborns (ELGANs) who are intubated at 3-10 days of age. Daily doses (at
      the same dosage) will be administered to infants who remain intubated for a potential of 5
      total doses in each patient. Subsequent groups of 8 infants each will receive 0.05 mg/kg,
      0.10 mg/kg, and 0.15 mg/kg of budesonide in calfactant (up to 5 total doses in each patient).
      A total of up to 32 infants will be enrolled in the trial. The investigators will evaluate
      the clinical, laboratory and safety data from each group of treated infants to 28 days of age
      before moving to the next dosing level of budesonide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical and anti-inflammatory efficacy of escalating doses of budesonide suspended in calfactant and given into the lungs of ELGANs by monitoring respiratory severity score (RSS).</measure>
    <time_frame>28 days of life for each dosing group</time_frame>
    <description>Dose escalation will be defined as effective at the dose level in which 5 of 8 infants achieve the following:
Extubation within 72 hours of first dose or after &lt; 3 doses-without re-intubation before 28 days of age
RSS on nasal continuous positive airway pressure (NCPAP) &lt; 1.5 or on nasal cannula Fi02 &lt;25% at &lt; 2L/min at 28 days of age, persisting for at least 72 hours.
Cumulative supplemental oxygen &lt; 4.2 from time of enrollment to 28 days of age 4 (see calculation below)
No respiratory support at 28 days, including no supplemental oxygen by nasal cannula
AND a &gt; 50% suppression of the tracheal aspirate interleukin-8 (IL-8) or CCL2 (chemokine ligand 2) at 24-72 hours (or prior to extubation if occurs at &lt;24 hours after dosing) after the initial dose in 5 of 8 of the infants (this may be a different combination of 5 patients than those who met the above criteria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The clinical and anti-inflammatory efficacy of escalating doses of budesonide suspended in calfactant and given into the lungs of ELGANs by monitoring tracheal aspirate cytokine levels.</measure>
    <time_frame>28 days of life for each dosing group</time_frame>
    <description>B. AND a &gt; 50% suppression of the tracheal aspirate interleukin-8 or chemokine ligand 2 at 24-72 hours (or prior to extubation if occurs at &lt;24 hours after dosing) after the initial dose in 5 of 8 of the infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events/Subject Safety</measure>
    <time_frame>Through 28 days of life</time_frame>
    <description>Safety assessments will include the subject's vital signs, clinical laboratory testing, morbidities associated with prematurity, morbidities associated with administration of budesonide in calfactant, and Adverse Events (AE)s. Clinical parameters/ AEs of interest are those potentially consistent with elevated glucocorticoid levels and will be specifically evaluated. A Data and Safety Monitoring Board (DSMB) will be established to review safety data. All of the data will be reviewed to monitor subject safety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial Budesonide Levels</measure>
    <time_frame>At 15 minutes, 1 and 4 hours after first dose and prior to each additional dose</time_frame>
    <description>The research team will obtain dried blood spot samples at 15 minutes, and 1 and 4 hours after the first dose of budesonide in calfactant for budesonide levels. Trough concentrations (Cmin) will be drawn before potential subsequent daily doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Airway Pressure and Oxygen Requirement at 28 Days of Age</measure>
    <time_frame>28 days of life for each dosing group</time_frame>
    <description>Clinical respiratory status (RSS and oxygen requirement) around dosing and at 28 days of age will be compared between dosing groups and also compared to the matched historical control patients from the &quot;Trial of Late Surfactant:(TOLSURF) study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Airway Pressure and Oxygen Requirement Correlated to Budesonide levels</measure>
    <time_frame>28 days of life for each dosing group</time_frame>
    <description>The individual patient's decrease in RSS will be correlated with their budesonide exposure measures by the area under the concentration time curve (AUC).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Bronchopulmonary Dysplasia (BPD)</condition>
  <arm_group>
    <arm_group_label>0.025 mg/kg Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.025 mg/kg Budesonide in Calfactant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.050 mg/kg Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.050 mg/kg Budesonide in Calfactant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.10 mg/kg Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.10 mg/kg Budesonide in Calfactant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.15 mg/kg Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mg/kg Budesonide in Calfactant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide in Calfactant</intervention_name>
    <description>Budesonide in Calfactant</description>
    <arm_group_label>0.025 mg/kg Budesonide</arm_group_label>
    <arm_group_label>0.050 mg/kg Budesonide</arm_group_label>
    <arm_group_label>0.10 mg/kg Budesonide</arm_group_label>
    <arm_group_label>0.15 mg/kg Budesonide</arm_group_label>
    <other_name>pulmicort respule</other_name>
    <other_name>calfactant</other_name>
    <other_name>budesonide</other_name>
    <other_name>0186-1986-04</other_name>
    <other_name>infasurf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt; 23 0/7 and &lt; 27 6/7 weeks of gestational age based on center's best estimate of due
             date (using earliest obstetrical ultrasound, last menstrual period, examination, and
             other pertinent available information)

          2. Day of life 3-14 from the date and time of delivery, with the date of birth being DOL
             0

          3. Intubated and mechanically ventilated and do not anticipate extubation in next 24
             hours

        Exclusion Criteria:

          1. Serious congenital malformations or chromosomal abnormality

          2. Likely to be extubated in next 24 hours

          3. Clinically unstable

          4. Infants who have received systemic steroids prior to dosing with study medication.

          5. Infants who have received Indocin, Ibuprofen, or acetaminophen ≤ 96 hours prior to
             enrollment window ending
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia McEvoy, MD, MCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia McEvoy, MD, MCR</last_name>
    <phone>503-494-0085</phone>
    <email>mcevoyc@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin F Milner, BS, CMA</last_name>
    <phone>503-494-0223</phone>
    <email>milner@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Keller, MD</last_name>
      <phone>415-514-3192</phone>
      <email>Roberta.Keller@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hudak, MD</last_name>
      <phone>904-244-3508</phone>
      <email>mark.hudak@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Barnette</last_name>
      <email>kimberly.barnette@jax.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Florida Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajan Wadhawan, MD</last_name>
      <email>rajan.wadhawan.md@flhosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health ans Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia McEvoy, MD, MCR</last_name>
      <phone>503-494-0085</phone>
      <email>mcevoyc@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Milner, BS, CMA</last_name>
      <phone>503-494-0223</phone>
      <email>milner@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jom-Henrdrik Weitkamp, MD</last_name>
      <phone>615-322-3476</phone>
      <email>hendrik.weitkamp@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Rogers, RN</last_name>
      <phone>615-343-6312</phone>
      <email>theresa.j.rogers@vanderbilt.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. doi: 10.1164/rccm.201505-0861OC.</citation>
    <PMID>26351971</PMID>
  </reference>
  <reference>
    <citation>Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008 May;121(5):e1310-8. doi: 10.1542/peds.2007-1973. Epub 2008 Apr 21.</citation>
    <PMID>18426851</PMID>
  </reference>
  <reference>
    <citation>Roberts JK, Stockmann C, Dahl MJ, Albertine KH, Egan E, Lin Z, Reilly CA, Ballard PL, Ballard RA, Ward RM. Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. Curr Clin Pharmacol. 2016;11(1):53-61.</citation>
    <PMID>26416605</PMID>
  </reference>
  <reference>
    <citation>Barrette AM, Roberts JK, Chapin C, Egan EA, Segal MR, Oses-Prieto JA, Chand S, Burlingame AL, Ballard PL. Antiinflammatory Effects of Budesonide in Human Fetal Lung. Am J Respir Cell Mol Biol. 2016 Nov;55(5):623-632.</citation>
    <PMID>27281349</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Cynthia McEvoy</investigator_full_name>
    <investigator_title>Principal Investigator, Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Steroids</keyword>
  <keyword>Extremely low gestational age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Calfactant</mesh_term>
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

